Mol Met:科学家发现治疗2型糖尿病的新一类药物!

2017-07-22 sunshine2015 来宝网

目前用于治疗肥胖症的药物也证明对2型糖尿病患者具有显著的健康益处。今天在分子代谢中发表的一项新研究解释了如何通过在我们的大脑中作用来实现2型糖尿病的治疗益处。



科学家发现治疗2型糖尿病的新方法】目前用于治疗肥胖症的药物也证明对2型糖尿病患者具有显着的健康益处。今天在分子代谢中发表的一项新研究解释了如何通过在我们的大脑中作用来实现2型糖尿病的治疗益处。

阿伯丁罗威特研究所大学的科学家与剑桥大学和密歇根大学的团队合作,发现药物洛卡色林通过改变神经元的活性来改善2型糖尿病,有助于调节血糖水平。

洛伐他汀是通过调节饥饿感来帮助患者减肥和起作用的。然而,研究人员发现,除此之外,药物还可以降低体内的葡萄糖水平,增加人体对胰岛素的敏感性。当身体不能产生足够的胰岛素或身体的细胞不能对胰岛素反应时,这导致2型糖尿病,意味着葡萄糖保留在血液中,而不是用作能量的燃料。

领导香港仔队的Lora Heisler教授解释说:“目前的2型糖尿病药物通过在身体中发挥作用而改善了这种疾病的症状,我们发现这种肥胖药物氯卡色林在大脑中起作用,以改善2型糖尿病。

“洛伐他汀针对重要的脑激素,称为原乳糖皮质素(POMC)肽,它们负责调节食欲,所以发送消息告诉我们,我们已经饱了,不再需要吃,导致体重减轻,POMC激素也激活一个不同的脑电路,有助于保持我们的血糖检查。

“这一发现很重要,因为2型糖尿病在现代世界是一个非常普遍的疾病,需要新的治疗选择。”

剑桥研究小组的领导Mark Evans博士补充说:“当然需要更多的研究,但这些有希望的发现为2型糖尿病药物治疗提供了全新的方向,这可能为那些为这种疾病而受苦的人提供希望。”

原始出处:

Luke K. Burke et al. Lorcaserin improves glycemic control via a melanocortin neurocircuit, Molecular Metabolism (2017). DOI: 10.1016/j.molmet.2017.07.004.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1896117, encodeId=e835189611e52, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Apr 27 06:10:00 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802443, encodeId=801c18024431c, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Fri Jun 08 19:10:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225296, encodeId=0da7225296e0, content=学习了,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sun Jul 23 07:42:32 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225186, encodeId=1e0122518688, content=学习了,好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Jul 22 22:30:53 CST 2017, time=2017-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225158, encodeId=54ea225158f8, content=科学家发现治疗2型糖尿病的新一类药物!, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRrYOibkVibW9vAkCfb2F55aHjqMoqUVaF9fuXIMCxexawSOsicpbF7Ria7o54zPK65PodlkwhPrNhLhS/0, createdBy=12f71314239, createdName=ann y, createdTime=Sat Jul 22 20:24:28 CST 2017, time=2017-07-22, status=1, ipAttribution=)]
    2018-04-27 一闲
  2. [GetPortalCommentsPageByObjectIdResponse(id=1896117, encodeId=e835189611e52, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Apr 27 06:10:00 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802443, encodeId=801c18024431c, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Fri Jun 08 19:10:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225296, encodeId=0da7225296e0, content=学习了,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sun Jul 23 07:42:32 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225186, encodeId=1e0122518688, content=学习了,好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Jul 22 22:30:53 CST 2017, time=2017-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225158, encodeId=54ea225158f8, content=科学家发现治疗2型糖尿病的新一类药物!, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRrYOibkVibW9vAkCfb2F55aHjqMoqUVaF9fuXIMCxexawSOsicpbF7Ria7o54zPK65PodlkwhPrNhLhS/0, createdBy=12f71314239, createdName=ann y, createdTime=Sat Jul 22 20:24:28 CST 2017, time=2017-07-22, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1896117, encodeId=e835189611e52, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Apr 27 06:10:00 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802443, encodeId=801c18024431c, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Fri Jun 08 19:10:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225296, encodeId=0da7225296e0, content=学习了,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sun Jul 23 07:42:32 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225186, encodeId=1e0122518688, content=学习了,好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Jul 22 22:30:53 CST 2017, time=2017-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225158, encodeId=54ea225158f8, content=科学家发现治疗2型糖尿病的新一类药物!, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRrYOibkVibW9vAkCfb2F55aHjqMoqUVaF9fuXIMCxexawSOsicpbF7Ria7o54zPK65PodlkwhPrNhLhS/0, createdBy=12f71314239, createdName=ann y, createdTime=Sat Jul 22 20:24:28 CST 2017, time=2017-07-22, status=1, ipAttribution=)]
    2017-07-23 惠映实验室

    学习了,谢谢。

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1896117, encodeId=e835189611e52, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Apr 27 06:10:00 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802443, encodeId=801c18024431c, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Fri Jun 08 19:10:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225296, encodeId=0da7225296e0, content=学习了,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sun Jul 23 07:42:32 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225186, encodeId=1e0122518688, content=学习了,好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Jul 22 22:30:53 CST 2017, time=2017-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225158, encodeId=54ea225158f8, content=科学家发现治疗2型糖尿病的新一类药物!, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRrYOibkVibW9vAkCfb2F55aHjqMoqUVaF9fuXIMCxexawSOsicpbF7Ria7o54zPK65PodlkwhPrNhLhS/0, createdBy=12f71314239, createdName=ann y, createdTime=Sat Jul 22 20:24:28 CST 2017, time=2017-07-22, status=1, ipAttribution=)]
    2017-07-22 1ddf0692m34(暂无匿称)

    学习了,好文章

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1896117, encodeId=e835189611e52, content=<a href='/topic/show?id=4a391158248' target=_blank style='color:#2F92EE;'>#MET#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11582, encryptionId=4a391158248, topicName=MET)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18fc139, createdName=一闲, createdTime=Fri Apr 27 06:10:00 CST 2018, time=2018-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1802443, encodeId=801c18024431c, content=<a href='/topic/show?id=acfae485578' target=_blank style='color:#2F92EE;'>#科学家发现#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=74855, encryptionId=acfae485578, topicName=科学家发现)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e572480, createdName=旅苦化文_208, createdTime=Fri Jun 08 19:10:00 CST 2018, time=2018-06-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225296, encodeId=0da7225296e0, content=学习了,谢谢。, beContent=null, objectType=article, channel=null, level=null, likeNumber=79, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sun Jul 23 07:42:32 CST 2017, time=2017-07-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225186, encodeId=1e0122518688, content=学习了,好文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Sat Jul 22 22:30:53 CST 2017, time=2017-07-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=225158, encodeId=54ea225158f8, content=科学家发现治疗2型糖尿病的新一类药物!, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRrYOibkVibW9vAkCfb2F55aHjqMoqUVaF9fuXIMCxexawSOsicpbF7Ria7o54zPK65PodlkwhPrNhLhS/0, createdBy=12f71314239, createdName=ann y, createdTime=Sat Jul 22 20:24:28 CST 2017, time=2017-07-22, status=1, ipAttribution=)]
    2017-07-22 ann y

    科学家发现治疗2型糖尿病的新一类药物!

    0

相关资讯

Diabetologia:心血管疾病生物标志物与2型糖尿病肾功能下降有关

近日,国际杂志 《Diabetologia》上在线发表一项关于心血管疾病生物标志物与2型糖尿病肾功能下降有关的研究。

Diabetologia:Semaglutide对2型糖尿病β细胞功能和血糖控制的影响

Semaglutide是用于治疗2型糖尿病的胰高血糖素样肽-1类似物。本研究评估其对一相和二相胰岛素分泌以及β细胞功能和血糖控制的影响。

J Diabetes Res:拔牙次数越多死亡率越高?

高敏C反应蛋白(hs-CRP)、拔牙次数和口腔感染对伴有或不伴有糖尿病的患者的死亡率的预测作用尚不清楚。该项前瞻性队列研究共纳入了12764名男性。通过问卷调查、血清测量、人体测量和血压测量获得了6434名老年男性的健康信息。其中425名男性检查为糖尿病患者。糖尿病和非糖尿病患者的基线特征有明显的差异。在糖尿病组,年龄和hs-CRP均有统计学意义,而在非糖尿病组则无此统计学意义,年龄、hs-CRP

从一例糖尿病患者的失明反思我们的患者教育问题

对于这件事,我作为糖尿病医生除了对李先生因不尊医嘱、胡乱投医而造成失明的痛苦表示十分痛心外,我也在深深地思考这悲剧的背后我们的糖尿病患者教育做的是否到位?

JACC:心血管医师要关注这两种新型糖尿病药物啦!

心血管并发症是糖尿病最重要的大血管并发症之一,许多针对糖尿病的治疗都建立在预防或者延缓心血管事件发生的基础上。2017年5月,发表在《J Am Coll Cardiol.》的一项综述讨论了钠葡萄糖协同转运蛋白2抑制剂(SGLT-2)和胰高血糖素样肽-1受体激动剂(GLP-1)能使2型糖尿病患者心血管获益的潜在机制,并对心血管医师使用这些药物提出建议。

2016共识声明:患有糖尿病和慢性肾病患者应用抗糖尿病药物的剂量调整

糖尿病患者肾功能衰退对于临床医生来讲具有挑战性,包括并发症的管理例如,高血压高脂血症,心血管疾病,贫血等。本文主要针对糖尿病和慢性肾病患者应用抗糖尿病药物的剂量调整提出指导建议。